Parkinson's

US, Australia Issue Patents on Sonde’s Voice-analysis Technology for Diagnosing Diseases

The United States and Australia have issued patents on Sonde Health‘s voice-analysis technology for diagnosing and monitoringĀ multiple sclerosisĀ and other diseases that affect speech. Sonde, which has dubbed its invention vocal biomarker technology, said the U.S. patent is Ā 9,936,914 and the Australian oneĀ 2014374349. Both patents cover Sonde’s…

1st Patient Enrolls in Phase 3 Trial of ADS-5102 as Way of Improving Walking Ability, Adamas Announces

A Phase 3 trial testing an oral once-a-day therapy ā€” ADS-5102 (amantadine) extended release capsules ā€” inĀ multiple sclerosis (MS) patients with walking difficulties has enrolled its first participant, Adamas Pharmaceuticals announced. The multi-center, double-blind study (NCT03436199) will assess ADS-5102 in about 570 such patients at five sites…

MS Patients Are Among the Most Satisfied with Their Healthcare, Surveys Show

Multiple sclerosisĀ patients are among those with debilitating diseases who are most satisfied with their healthcare, two surveys indicate. Others who are satisfied include people withĀ amyotrophic lateral sclerosisĀ and Parkinsonā€™s, according to the questionnaire-basedĀ PatientsLikeMeĀ research. In contrast, people with fibromyalgia, post-traumatic stress disorder (PTSD) and major depressive disorder…

Adamas Reports Positive Results in Study of Drug to Treat MS Patients with Walking Difficulties

Adamas Pharmaceuticals recently reported positive results from its Phase 2 proof-of-concept clinical trial evaluating ADS-5102 (amantadine HCl), an extended-release version of amantadine, inĀ multiple sclerosis (MS) patients with difficulties inĀ walking. The trial (NCT02471222),Ā aĀ double-blind, placebo-controlled and two-arm parallel groupĀ study,Ā evaluated ADS-5102 given once dailyĀ at 340 mg, at bedtime, for four…